Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Common Equity (2016 - 2025)

CV Sciences (CVSI) has disclosed Common Equity for 14 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 18.22% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 18.22% year-over-year, with the annual reading at $1.5 million for FY2025, 18.22% down from the prior year.
  • Common Equity hit $1.5 million in Q4 2025 for CV Sciences, down from $1.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $12.0 million in Q1 2021 to a low of -$777000.0 in Q4 2022.
  • Historically, Common Equity has averaged $3.7 million across 5 years, with a median of $2.4 million in 2024.
  • Biggest five-year swings in Common Equity: plummeted 121.93% in 2022 and later surged 473.62% in 2023.
  • Year by year, Common Equity stood at $3.5 million in 2021, then tumbled by 121.93% to -$777000.0 in 2022, then soared by 473.62% to $2.9 million in 2023, then crashed by 38.17% to $1.8 million in 2024, then dropped by 18.22% to $1.5 million in 2025.
  • Business Quant data shows Common Equity for CVSI at $1.5 million in Q4 2025, $1.5 million in Q3 2025, and $1.8 million in Q2 2025.